Filing Date   Title Clause Samples

Filing Date   Title. 12/099687 08-Apr-2008 SYSTEMS AND METHODS FOR Ex vivo LUNG CARE 13/446706 13-Apr-2012 ORGAN CARE SOLUTION FOR EX-VIVO MACHINE PERFUSION OF DONOR LUNGS 14/464426 20-Aug-2014 SYSTEMS AND METHODS FOR EX VIVO ORGAN CARE 14/728771 02-.▇▇▇-2015 EX VIVO ORGAN CARE SYSTEM 14/734769 09-.Tun-2015 SYSTEMS, METHODS, COMPOSITIONS AND SOLUTIONS FOR PERFUSING AN ORGAN 14/939845 12-Nov-2015 SYSTEMS AND METHODS FOR EX-VIVO ORGAN CARE 15/207303 1 l-Jul-2016 SYSTEMS FOR MONITORING AND APPLYING ELECTRICAL CURRENTS IN AN ORGAN PERFUSION SYSTEM 15/258194 07-Sep-2016 AORTIC CANNULA FOR EX VIVO ORGAN CARE SYSTEM 15/857953 29-Dec-2017 SYSTEMS AND METHODS FOR EX-VIVO ORGAN CARE AND FOR USING LACTATE AS AN INDICATION OF DONOR ORGAN STATUS 728233 Australia 23-Sept-1998 COMPOSITIONS, METHODS AND DEVICES FOR MAINTAINING AN ORGAN September 23, 2018 2005294206 Australia 07-0ct-2005 SYSTEMS AND METHODS FOR EX- VIVO ORGAN CARE October 7, 2025 2008260409 Australia 24-Apr-2008 SYSTEMS AND METHODS FOR EX- VIVO ORGAN CARE USING LACTATE AS AN INDICATOR April 24, 2028 2009212725 Australia 30-Jan-2009 SYSTEMS AND METHODS FOR EX VIVO LUNG CARE January 30, 2029 2012216796 Australia 07-0ct-2005 SYSTEMS AND METHODS FOR EX- VIVO ORGAN CARE October 7, 2025 2012242578 Australia 13-Apr-2012 ORGAN CARE SOLUTION FOR EX- VIVO MACHINE PERFUSION OF DONOR LUNGS April 13, 2032 2013216566 Australia 07-0ct-2005 SYSTEMS AND METHODS RELATED TO ORGAN PRESERVATION October 7, 2025 2014202736 Australia 30-Jan-2009 METHOD AND DEVICE THAT PRESERVES LUNGS EX VIVO January 30, 2029 2014256394 Australia 07-0ct-2005 SYSTEMS AND METHODS FOR EX- VIVO ORGAN CARE October 7, 2025 2015202735 Australia 30-Jan-2009 METHOD AND DEVICE THAT PRESERVES LUNGS EX VIVO January 30, 2029 2015246083 Australia 07-0ct-2005 SYSTEMS AND METHODS RELATING TO ORGAN PRESERVATION October 7, 2025 2016201793 Australia 24-Apr-2008 SYSTEMS AND METHODS FOR EX- VIVO ORGAN CARE USING LACTATE AS AN INDICATOR April 24, 2028 2016222388 Australia 07-0ct-2005 SYSTEMS AND METHODS FOR EX- VIVO ORGAN CARE October 7, 2025 1017274 Austria 23-Sep-1998 COMPOSITIONS, METHODS AND DEVICES FOR MAINTAINING AN ORGAN September 23, 2018 1017274 Belgium 23-Sep-1998 COMPOSITIONS, METHODS AND DEVICES FOR MAINTAINING AN ORGAN September 23, 2018 1768490 Belgium 07-0ct-2005 SYSTEMS AND METHODS RELATING TO ORGAN PRESERVATION October 7, 2025 1942726 Belgium 19-Apr-2007 SYSTEMS AND METHODS FOR EX VIVO ORGAN CARE April 19, 2027 2150105 Belgium 24-Apr-2008 SYSTEMS AND METHODS FOR EX VIVO OR...
Filing Date   Title. Canada 2434642C 9-Aug-01 Wireless communication networks for providing remote monitoring of devices

Related to Filing Date   Title

  • Closing Date Balance Sheet (a) Within thirty (30) days after the Closing Date, Buyer shall prepare and deliver to Shareholders' Representative a draft Closing Date Balance Sheet, which shall be prepared (i) in accordance with GAAP applied in a manner consistent with the past practice of the Company, except as otherwise specifically required by the Net Worth Methodology and (ii) in a manner consistent with the December Balance Sheet. (b) If Shareholders' Representative has no objections to the draft Closing Date Balance Sheet, such draft shall constitute the Closing Date Balance Sheet. If Shareholders' Representative has any objections to the draft Closing Date Balance Sheet, it will deliver a detailed statement describing its objections to Buyer within thirty (30) days after receiving the draft Closing Date Balance Sheet. Shareholders' Representative and Buyer will use their commercially reasonable efforts to resolve any such objections. If Shareholders' Representative duly gives Buyer such notice of objection, and if Buyer and Shareholders' Representative fail to resolve the issues outstanding with respect to the Closing Date Balance Sheet and the calculation of the Closing Date Net Worth within thirty (30) days of Buyer's receipt of Shareholders' Representative's objection notice, Buyer and Shareholders' Representative shall submit the issues remaining in dispute to PricewaterhouseCoopers, certified public accountants (the "Independent Accountants"). If issues remaining in dispute are submitted to the Independent Accountants for resolution, (i) Buyer and Shareholders' Representative shall promptly furnish or cause to be furnished to the Independent Accountants such work papers and other documents and information relating to the disputed issues as the Independent Accountants may request and are available to that party or its agents and shall be afforded the opportunity to present to the Independent Accountants any material relating to the disputed issues and to discuss the issues with the Independent Accountants; (ii) the determination by the Independent Accountants, as set forth in a notice to be delivered to both Buyer and Shareholders' Representative within thirty (30) days of the submission to the Independent Accountants of the issues remaining in dispute, shall be final, binding and conclusive on the parties and shall be used in the calculation of the Closing Date Net Worth; and (iii) Buyer shall bear fifty percent (50%) of the fees and costs of the Independent Accountants for such determination and fifty percent (50%) of such fees and expenses shall be paid from the Escrow Fund. (c) Buyer will make the work papers used in preparing the draft Closing Date Balance Sheet and the Closing Date Balance Sheet available to Shareholders' Representative at reasonable times and upon reasonable notice at any time during the preparation by Buyer of the draft Closing Date Balance Sheet and the resolution of any objections with respect thereto.

  • Effective Date; Term This Agreement shall become effective on the date of its execution and shall remain in force for a period of two (2) years from such date, and from year to year thereafter but only so long as such continuance is specifically approved at least annually by the vote of a majority of the Trustees who are not interested persons of the Trust or the Adviser, cast in person at a meeting called for the purpose of voting on such approval, and by a vote of the Board of Trustees or of a majority of the outstanding voting securities of the Fund. The aforesaid requirement that this Agreement may be continued "annually" shall be construed in a manner consistent with the Act and the rules and regulations thereunder.

  • Contents of Registration Statement (i) The Registration Statement, when it became effective, did not contain and, as amended or supplemented, if applicable, will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii) the Registration Statement and the Prospectus comply and, as amended or supplemented, if applicable, will comply in all material respects with the Securities Act and the applicable rules and regulations of the Commission thereunder and (iii) the Prospectus does not contain and, as amended or supplemented, if applicable, will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, except that the representations and warranties set forth in this paragraph do not apply to statements or omissions in the Registration Statement or the Prospectus based upon information relating to any Underwriter furnished to the Company in writing by such Underwriter through you expressly for use therein.

  • Additional Registration Statements Until the Applicable Date (as defined below) and at any time thereafter while any Registration Statement is not effective or the prospectus contained therein is not available for use or any Current Public Information Failure (as defined in the Registration Rights Agreement) exists, the Company shall not file a registration statement or an offering statement under the 1933 Act relating to securities that are not the Registrable Securities (other than a registration statement on Form S-8 or such supplements or amendments to registration statements that are outstanding and have been declared effective by the SEC as of the date hereof (solely to the extent necessary to keep such registration statements effective and available and not with respect to any Subsequent Placement)). “Applicable Date” means the earlier of (x) the first date on which the resale by the Buyers of all the Registrable Securities required to be filed on the initial Registration Statement (as defined in the Registration Rights Agreement) pursuant to the Registration Rights Agreement is declared effective by the SEC (and each prospectus contained therein is available for use on such date) or (y) the first date on which all of the Registrable Securities are eligible to be resold by the Buyers pursuant to Rule 144 (or, if a Current Public Information Failure has occurred and is continuing, such later date after which the Company has cured such Current Public Information Failure).

  • Closing Date Certificate Borrower shall have delivered to Administrative Agent an originally executed Closing Date Certificate, together with all attachments thereto.